What is Accro Bioscience?
Accro Bioscience is a specialized biotechnology firm dedicated to the investigation of regulated cell death pathways, including necroptosis, pyroptosis, and ferroptosis. These biological processes are increasingly recognized as pivotal factors in the pathogenesis of various human diseases, positioning the company at the forefront of precision medicine. By focusing on the molecular mechanisms that govern cell survival and demise, Accro Bioscience aims to develop novel therapeutic candidates that address significant unmet medical needs. The company's research-driven approach has attracted substantial interest from institutional investors, facilitating its transition from early-stage development to a mature, enterprise-level organization capable of navigating complex regulatory and clinical environments.
How much funding has Accro Bioscience raised?
Accro Bioscience has raised a total of $62M across 2 funding rounds:
Series B
$12M
Series C
$50M
Series B (2025): $12M with participation from Shenzhen Capital Group Co., Ltd, Leader-innovations Venture Fund, and Morningside Venture Capital
Series C (2026): $50M led by OrbiMed, Shenzhen Capital Group Co., Ltd, Central Building Services Group, Oriza Holdings, and TCG Crossover
Key Investors in Accro Bioscience
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various stages of development.
Shenzhen Capital Group Co., Ltd
Shenzhen Capital Group Co., Ltd (SCGC) is a prominent state-owned venture capital firm affiliated with the Shenzhen Government, known for its extensive investment activity in industries supported by national strategic policies.
TCG Crossover
TCG Crossover (TCGX) is a science-driven investment firm that focuses on advancing disruptive medicines and supporting innovators in the pharmaceutical and biotechnology sectors.
What's next for Accro Bioscience?
With the successful completion of its latest funding round, Accro Bioscience is poised to enter a transformative phase of growth. The strategic roadmap likely involves the advancement of lead candidates into more rigorous clinical trials and the potential expansion of its research infrastructure to support broader therapeutic indications. As the company scales, it will likely focus on optimizing its intellectual property portfolio and exploring strategic partnerships to enhance its commercialization capabilities. The continued support from high-profile investors suggests a long-term commitment to the company's mission of pioneering breakthrough medicines, ensuring that Accro Bioscience remains a key player in the future of molecular therapeutics and disease management.
See full Accro Bioscience company page
